Multiple myeloma treatment: choosing the first treatment plan

Confirm which plasma-cell condition is present

An abnormal monoclonal protein can occur in MGUS, smoldering myeloma or active multiple myeloma. The distinction uses blood and urine tests, marrow findings, imaging and evidence of organ effects or other myeloma-defining features. It determines whether treatment is needed and what kind.

Active disease may cause high calcium, kidney impairment, anemia or bone damage. Specific high-risk biomarkers can also establish a need for treatment before obvious symptoms appear. Ask the hematologist to identify the finding that establishes your diagnosis and the reason for starting treatment now.

Sources and references: [1] [2]

Smoldering myeloma has its own risk-based discussion

People with smoldering myeloma need an assessment of progression risk and a monitoring plan. For high-risk disease, treatment may also be discussed. In November 2025, the FDA approved daratumumab and hyaluronidase-fihj for adults with high-risk smoldering myeloma in the United States.

Ask whether you meet a high-risk definition and how the proposed monitoring or treatment compares for your case. If considering care in Shanghai, the team should review the local indication and available options. Keep the plan separate from the multi-drug approach used for active myeloma.

Sources and references: [3] [1]

Use disease risk and fitness together

Marrow genetic findings, stage-related blood tests, kidney function and disease outside the marrow help the team understand risk. Your fitness, other illnesses, existing nerve symptoms and ability to attend treatment also affect the choice. Age is part of this assessment, alongside how you manage ordinary activities.

Tell the team about walking, falls, memory, appetite and the help you have at home. These details can shape doses and scheduling. Ask which parts of the plan are driven by the myeloma's biology and which are being adapted to make treatment manageable for you.

Sources and references: [1]

Initial treatment often combines several drug classes

A common approach uses medicines that act in different ways, such as a proteasome inhibitor, an immunomodulatory drug, an anti-CD38 antibody and a steroid. One example is daratumumab with bortezomib, lenalidomide and dexamethasone, often abbreviated D-VRd. Other combinations may be selected according to fitness, kidney function and availability.

Four-drug treatment is used in several contemporary settings, but the regimen and intensity should fit the person. In January 2026, the FDA also approved D-VRd for adults with newly diagnosed myeloma who are ineligible for autologous transplant. Ask for the full medicine list and what each drug contributes.

Sources and references: [1] [4]

Discuss autologous transplant early enough to plan

For eligible patients, an autologous stem cell transplant may follow initial therapy as consolidation. Stem cells are collected and stored, high-dose treatment is given, and the cells are returned to restore blood production. The discussion includes expected disease control, recovery and effects on daily life.

Ask whether transplant is recommended now, could be deferred in your circumstances or is unsuitable because of health factors. If collection is planned, clarify its timing before the initial treatment course is too far advanced. Your preference matters, and the team should explain the trade-offs in the proposed sequence.

Sources and references: [5] [1]

Plan for treatment after the first response

Myeloma care often continues with maintenance or another ongoing regimen after the initial phase. The choice depends on disease risk, earlier treatment, response and tolerability. Ask how frequently you will receive medicine, what monitoring is needed and which side effects should prompt a review.

Response is followed using the tests that reflect your disease, such as protein levels, free light chains, marrow assessment and imaging. MRD testing may add information about response depth. Ask how each result will be used before assuming it changes the treatment schedule.

Sources and references: [1] [2]

Protect bones, kidneys and immune function

Supportive treatment can reduce complications while the myeloma is being controlled. Bone-strengthening medicines may be recommended, with attention to kidney function, calcium and dental health. The team also considers infection prevention, clot prevention for relevant regimens and management of pain or anemia.

Report reduced urine output, severe new back pain, weakness or numbness in the legs, or fever promptly. Ask which symptoms require emergency assessment. Bring all medicines and supplements to the consultation so that the team can identify interactions and avoid unnecessary strain on the kidneys.

Sources and references: [1] [2]

Prepare a first-treatment review in Shanghai

Gather the marrow report, flow cytometry, genetic testing, protein and light-chain results, blood counts, calcium and kidney tests, and the imaging used for staging. Include any treatment already started and the reason for seeking another opinion.

EastMedGo can help organize a hematology treatment review in Shanghai, where Ruijin Hospital is one available hematology resource. Contact our team with the diagnosis and your immediate decision. We can help clarify appointment requirements and arrange the records so the consultation addresses the first regimen, transplant planning and follow-up logistics.

Sources and references: [6]

Common questions